Category: News

Post

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7, 2018 San Francisco, CA  USA Iclaprim data will be presented at the conference in a poster,...

September 20, 2018September 20, 2018by In News
Post

Melinta Therapeutics Names Peter Milligan as Chief Financial Officer

NEW HAVEN, Conn. , Sept. 18, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter Milligan as its new READ FULL TEXT

September 18, 2018September 18, 2018by In News
Post

Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress

Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®) DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 17, 2018 /PRNewswire/ —  Theravance Biopharma, Inc. READ FULL TEXT

September 17, 2018September 17, 2018by In News
Post

Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors

Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO–(BUSINESS WIRE)–Sep. 12, 2018– Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of industry leader David Gollaher, Ph.D., to the company’s Board of Directors....

September 12, 2018September 12, 2018by In News
Post

Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018

Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO–(BUSINESS WIRE)–Sep. 12, 2018– Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating the broad clinical utility and potency of the company’s lead antifungal product candidate,...

September 12, 2018September 12, 2018by In News
Post

Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 11, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (” Theravance Biopharma “) and Mylan READ FULL TEXT

September 11, 2018September 11, 2018by In News
Post

T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on September 5, 2018 it issued inducement awards to three new employees.    These awards were made under T2 Biosystems’ Inducement...

September 7, 2018September 7, 2018by In News